A PHASE II MULTICENTER TRIAL OF INTRATUMORAL/INTERSTITIAL THERAPY WITH HN-6600

HN-66000是一种突变白喉的专利药物制剂 毒素和人类转铁蛋白，这是本开发作为一个潜在的治疗- 恶性脑肿瘤的I期临床试验的结果 美国国立卫生研究院的研究表明，该药物在患有 常规治疗难治性恶性脑肿瘤，无严重 神经毒性或全身毒性。 这一结果证明， 在第二阶段试验中扩大评估。

HN-66000 is a proprietary pharmaceutical formulation of mutant diphthieria toxin and human transferrin that is beng developed as a potential treat- ment for malignant brain tumors.The results from Phase I trial sponsored by the NIH suggest that the drug produces tumor responses in patients with malignant brain tumors refractory to conventional therapy without severe neurologic or systemic toxcicity. The encoraging results warrant an expanded evaluation in a phase II trail.